Drug Profile
PEG anti-ICAM monoclonal antibody
Alternative Names: BIRR 10/PEG; pegylated anti-ICAM MAbLatest Information Update: 14 Jun 2001
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Jun 2001 No-Development-Reported for Cancer in European Union (Unknown route)
- 23 May 1997 Preclinical development for Cancer in European Union (Unknown route)
- 16 May 1997 Preclinical development for Cancer in Germany (Unknown route)